Expands Pfizer’s rare disease portfolio with potential first-in-class therapy for achondroplasia, a genetic condition and the most common form of…
Therachon
BASEL, Switzerland, February 14, 2018 – Therachon AG, a biotechnology company focused on rare genetic diseases, today announced the dosing of…
BASEL, Switzerland — June 20, 2017 – Therachon AG, a biotechnology company focused on rare genetic diseases, announced today that the…
The Chandler Project 🦋
The Chandler Project provides those affected with achondroplasia, and other forms of dwarfism and skeletal dysplasia, with the latest in pharmaceutical research and surgical advancements. The Chandler Project believes in advocacy, awareness, support, and hope for all.